Brett Burrell - Harrow Health Vice Compliance
| HROW Stock | USD 40.02 1.84 4.40% |
Executive
Brett Burrell is Vice Compliance of Harrow Health
| Address | 102 Woodmont Boulevard, Nashville, TN, United States, 37205 |
| Phone | 615 733 4730 |
| Web | https://www.harrow.com |
Harrow Health Management Efficiency
The company has return on total asset (ROA) of (0.0168) % which means that it has lost $0.0168 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5023) %, meaning that it created substantial loss on money invested by shareholders. Harrow Health's management efficiency ratios could be used to measure how well Harrow Health manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to climb to 0 in 2024, whereas Return On Tangible Assets are likely to drop (0.17) in 2024. At this time, Harrow Health's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 146.5 M in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (2 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mustapha Parekh | Design Therapeutics | N/A | |
| Xiaolin Wang | Revolution Medicines | 53 | |
| Matthew JD | Enanta Pharmaceuticals | 51 | |
| Patrik Esq | Amicus Therapeutics | N/A | |
| Keith Marschke | Ligand Pharmaceuticals Incorpor | N/A | |
| Kathleen Borthwick | Passage Bio | 47 | |
| Andrew JD | Ligand Pharmaceuticals Incorpor | 49 | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| Todd Pettingill | Ligand Pharmaceuticals Incorpor | N/A | |
| Marc Wilson | Crinetics Pharmaceuticals | 45 | |
| Jan Smith | Revolution Medicines | N/A | |
| Patrick Lucy | Ligand Pharmaceuticals Incorpor | N/A | |
| Michael Jeong | Ligand Pharmaceuticals Incorpor | N/A | |
| Matthew JD | Lyell Immunopharma | 48 | |
| Ellen JD | Amicus Therapeutics | 61 | |
| Karl Whitney | Passage Bio | N/A | |
| Simon Harford | Amicus Therapeutics | 64 | |
| Tara Kieffer | Enanta Pharmaceuticals | 46 | |
| Edna Maneval | Oric Pharmaceuticals | 64 | |
| JD Esq | Passage Bio | 60 | |
| Jayne Gershkowitz | Amicus Therapeutics | 67 | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.0168 |
Harrow Health Leadership Team
Elected by the shareholders, the Harrow Health's board of directors comprises two types of representatives: Harrow Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Harrow. The board's role is to monitor Harrow Health's management team and ensure that shareholders' interests are well served. Harrow Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Harrow Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert DDS, Special Advisor | ||
| Jamie Webb, Director Relations | ||
| David Moufarrge, VP Technology | ||
| RPh Mannebach, Head Pharmacovigilance | ||
| Brett Burrell, Vice Compliance | ||
| CFA CMA, CFO Sec | ||
| Andrew Livingston, Chief Officer | ||
| Larry MD, Chief Officer | ||
| Mark JD, CEO Chairman | ||
| Kim Barratt, Chief Officer | ||
| Greg DiPasquale, Senior Commercial | ||
| John MBA, Chief Officer | ||
| Dennis PharmD, Chief Strategy | ||
| CMA CFA, CFO Secretary |
Harrow Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Harrow Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.0168 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 1.61 B | ||||
| Shares Outstanding | 35.61 M | ||||
| Shares Owned By Insiders | 14.11 % | ||||
| Shares Owned By Institutions | 59.17 % | ||||
| Number Of Shares Shorted | 2.51 M | ||||
| Price To Earning | 24.45 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Harrow Stock Analysis
When running Harrow Health's price analysis, check to measure Harrow Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harrow Health is operating at the current time. Most of Harrow Health's value examination focuses on studying past and present price action to predict the probability of Harrow Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harrow Health's price. Additionally, you may evaluate how the addition of Harrow Health to your portfolios can decrease your overall portfolio volatility.